Translational Psychiatry

Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

Translational Psychiatry精神病学领域排名最高的开放获取期刊，旨在弥合神经科学知识爆炸与患者概念新颖治疗之间的差距。神经科学知识的爆炸式增长与为我们的患者提供的概念新颖的治疗之间存在着巨大的差距，这些治疗将比现有方法提供更好的结果。 转化精神病学通过关注直接研究精神疾病并将新发现带入临床实践的论文来弥补这一差距。 除了期刊的这一核心使命之外，我们还可以考虑来自医学研究所有领域的论文，包括但不限于分子生物学、遗传学、药理学、成像和流行病学，这些论文有可能有助于增强医学研究领域的水平。 更广泛的转化精神病学。